Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

OBJECTIVE: The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical Study Report (CSR) and that in the 2017 prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Erviti, Juan, Wright, James, Bassett, Ken, Ben-Eltriki, Mohamed, Jauca, Ciprian, Saiz, Luis Carlos, Leache, Leire, Gutiérrez-Valencia, Marta, Perry, Thomas L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809302/
https://www.ncbi.nlm.nih.gov/pubmed/36585131
http://dx.doi.org/10.1136/bmjopen-2021-060172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809302/
https://www.ncbi.nlm.nih.gov/pubmed/36585131
http://dx.doi.org/10.1136/bmjopen-2021-060172

Ejemplares similares